TITLE

Issues related to risk evaluation and mitigation strategies in health-system pharmacy

AUTHOR(S)
Coffey, Justine
PUB. DATE
September 2010
SOURCE
American Journal of Health-System Pharmacy;9/15/2010, Vol. 67 Issue 18, p1512
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The article presents the author's views on the issues focusing on the risk evaluation and mitigation strategies (REMSs) in health-system pharmacy. He is of the opinion that patient access to some medications could be compromised if the pharmacy's input and involvement in the development of REMSs is not considered. He believes that the U.S. Food and Drug Administration (FDA) should consult the pharmacists and utilize their expertise in addressing the issues that hinder the development of REMSs.
ACCESSION #
53432605

 

Related Articles

  • Fraud in the pharmacy? Pray, W. Steven // Drug Topics;Sep2014, Vol. 158 Issue 9, p12 

    The author discusses the fraud in pharmacy in the U.S. He mentions about the definition of health fraud by the U.S. Food and Drug Administration (FDA) as misleading advertisements and promotions of health care products. He states that inclusion of legitimate vitamins and minerals is missing in...

  • A renewed interest in compounding. Lunner, Kristina E. // Pharmacy Today;Sep2006, Vol. 12 Issue 9, p34 

    The article focuses on the pharmacist compounding, a core element of the practice of pharmacy, which has gained congressional interest. A briefing for Hill staff on pharmacist compounding was co-sponsored by the U.S. legislators. The briefing was designed to educate staff about the topic...

  • Letters. Wheelock, Anne; Prazenica, Jennifer; Katz, Robert S. // Drug Topics;Apr2012, Vol. 156 Issue 4, p4 

    Several letters to the editor are presented in response to articles in previous issues including pharmacists complaining about their job, in the November 2011 issue, retail setting in hospital pharmacy, and "New diet drug overwhelmingly endorsed by FDA committee," in the February 23, 2012 issue.

  • Potential Risks of Pharmacy Compounding. Gudeman, Jennifer; Jozwiakowski, Michael; Chollet, John; Randell, Michael // Drugs in R&D;2013, Vol. 13 Issue 1, p1 

    Pharmacy compounding involves the preparation of customized medications that are not commercially available for individual patients with specialized medical needs. Traditional pharmacy compounding is appropriate when done on a small scale by pharmacists who prepare the medication based on an...

  • Drug Labeling Seminar Provides Industry Updates.  // Townsend Letter for Doctors & Patients;May2004, Issue 250, p18 

    Presents information on the seminar sponsored by the American Association of Homeopathic Pharmacists in Washington, D.C. in September 2003. Focus of seminars on drug labeling requirements and the Food and Drug Administration and Federal Trade Commission's scrutiny of product label claims;...

  • FDA says it's not against compounding. Foxhall, Kathryn // Drug Topics;10/8/2007, Vol. 151 Issue 19, p6 

    This article reports that the U.S. Food and Drug Administration is not against compounding of drugs. Steven Silverman, a key enforcement officer in U.S. Food and Drug Administration, indicated that the FDA wants to look for opportunities to engage in coordinated action with state boards against...

  • THE FOOD AND DRUG ADMINISTRATION AND THE PHARMACY PROFESSION: PARTNERS TO ENSURE THE SAFETY AND EFFICACY OF PHARMACOGENOMIC THERAPY. SPRENG, JENNIFER E. // Journal of Health Care Law & Policy;2010, Vol. 13 Issue 1, p77 

    The article deals with the partnership of the U.S. Food and Drug Administration (FDA) and the pharmacy profession to ensure the safety and efficacy of pharmacogenomic therapy. The developments in pharmacy practice that make pharmacists well-positioned to serve as a backstop to the prescription...

  • Long-awaited opioid REMS affects prescribers more than dispensers. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;6/1/2011, Vol. 68 Issue 11, p963 

    No abstract available.

  • FDA Drug Safety Podcasts: Resources for drug information. Wu, Kimberly; Shepherd, Jennifer; Jackson, Steven; Chew, Catherine // Journal of the American Pharmacists Association: JAPhA;Mar/Apr2013, Vol. 53 Issue 2, p188 

    Objective: To describe a Web-based drug information service provided by the Food and Drug Administration (FDA) to increase the reach of Drug Safety Communications to pharmacists and other health professionals. Setting: The Division of Drug Information (DDI) within the FDA Center for Drug...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics